Bayer AG vs. Lupin Limited: Rivaroxaban Patent Dispute Ends in Dismissal

Case Overview

In a closely watched pharmaceutical patent dispute, Bayer AG’s infringement action against Lupin Limited over the blockbuster anticoagulant XARELTO® (rivaroxaban) concluded with a stipulated dismissal with prejudice in the Delaware District Court. Filed on December 10, 2021, and closed on January 28, 2026, Case No. 1:21-md-03017 spanned approximately 1,510 days — a timeline reflective of the complex, multi-defendant pharmaceutical patent litigation landscape that defines ANDA (Abbreviated New Drug Application) disputes under the Hatch-Waxman Act.

The case centered on U.S. Patent No. US-10828310-B2, a formulation or method-of-use patent protecting XARELTO®, one of the world’s best-selling oral anticoagulants. For patent attorneys, IP professionals, and pharmaceutical R&D teams, the resolution of this rivaroxaban patent infringement case carries meaningful strategic and competitive intelligence value — particularly regarding how innovator pharmaceutical companies manage multi-party ANDA litigation and when negotiated exits serve broader IP portfolio objectives.

The Parties

The Patent at Issue

This case involved U.S. Patent No. US-10828310-B2, a formulation or method-of-use patent protecting XARELTO® (rivaroxaban). Design patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect ornamental appearance rather than functional technology.

• • US-10828310-B2 — Pharmaceutical formulation / anticoagulant therapy (rivaroxaban)

Legal Representation

Plaintiff Counsel: Morris, Nichols, Arsht & Tunnell LLP; Williams & Connolly LLP (Washington); and Robinson Miller LLC, with attorneys including Jack B. Blumenfeld, Bruce R. Genderson, Dov P. Grossman, and Alexander S. Zolan — a team reflecting top-tier Hatch-Waxman litigation expertise.

Defendant Counsel: Phillips, McLaughlin & Hall PA, represented by Deepro R. Mukerjee, Lance A. Soderstrom, and Jitty Malik, Ph.D., among others.

The Verdict & Legal Analysis

Outcome

The action between Bayer AG (together with Bayer Intellectual Property GmbH and Janssen Pharmaceuticals, Inc.) and Mankind Pharma Ltd. was terminated via stipulated dismissal with prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c). The dismissal explicitly stated that all claims and defenses asserted by both parties are dismissed with prejudice, and that each party bears its own costs, disbursements, and attorneys’ fees — a standard structure for negotiated pharmaceutical patent resolutions.

No damages award, royalty figure, or injunctive relief order is disclosed in the public record. The specific financial or licensing terms of any underlying settlement agreement, if one exists, were not publicly filed.

Verdict Cause Analysis

The case was initiated as an infringement action — the standard posture in Hatch-Waxman ANDA litigation, where the brand-name drug holder files suit upon receiving a Paragraph IV certification from a generic applicant asserting that the listed patents are invalid, unenforceable, or will not be infringed.

The dismissal with prejudice — rather than without prejudice — is legally significant. It forecloses Bayer and Janssen from re-filing the same claims against Mankind regarding US-10828310-B2. Conversely, Mankind cannot re-litigate its invalidity or non-infringement defenses. This bilateral finality strongly suggests the parties reached a confidential settlement agreement, likely including a negotiated generic entry date, a licensing arrangement, or a consent judgment — all common resolution mechanisms in Hatch-Waxman litigation.

The “each party bears its own costs” provision is a neutral cost allocation typically seen in negotiated resolutions rather than adjudicated outcomes, further supporting the inference of a negotiated exit.

Legal Significance

While no published claim construction order or validity ruling emerged from this particular defendant pairing, the MDL structure means that rulings in related actions within the same docket (involving other generic defendants) could carry significant persuasive weight for ongoing XARELTO® patent disputes. Patent practitioners should monitor the full MDL docket for any Markman rulings or summary judgment decisions that may have been issued against other defendants.

Strategic Takeaways

The resolution of Bayer v. Mankind within the broader XARELTO® MDL reflects a well-established pattern in blockbuster pharmaceutical patent litigation: innovators engage in coordinated, multi-front litigation to defend key formulation and method-of-use patents, while individual generic challengers pursue negotiated entry dates that provide commercial certainty.

XARELTO® remains a multi-billion-dollar franchise, making any generic entry commercially consequential. The Hatch-Waxman framework’s 30-month stay mechanism and first-filer exclusivity provisions create strong incentives for both negotiated settlements and continued IP enforcement.

For the broader pharmaceutical IP community, this case reinforces Delaware’s continued dominance as the preferred forum for complex ANDA patent disputes. It also highlights the enduring value of maintaining deep patent estates around commercial blockbusters — forcing generic challengers to navigate multiple validity and infringement hurdles across multiple patents simultaneously.

Companies developing generic anticoagulants or pursuing biosimilar strategies in adjacent therapeutic areas should treat this litigation as a competitive intelligence marker, tracking which generic entrants secured favorable resolution terms and on what timelines.